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Matrix Metalloproteinase Mediated 
Type I Collagen Degradation is an 
Independent Predictor of Increased 
Risk of Acute Myocardial Infarction 
in Postmenopausal Women
Ditte Marie Bertelsen1,2, Jesper Skov Neergaard3, Cecilie Liv Bager1, Signe Holm Nielsen3,4, 
Niels Henry Secher2, Jesper Hastrup Svendsen5, Asger Reinstrup Bihlet6, Jeppe Ragnar 
Andersen6, Morten Asser Karsdal3, Claus Christiansen1,3 & Henning Bay Nielsen1
Acute myocardial infarction (AMI) is often underdiagnosed in women. It is therefore of interest to 
identify biomarkers that indicate increased risk of AMI and thereby help clinicians to have additional 
focus on the difficult AMI diagnosis. Type I Collagen, a component of the cardiac extracellular matrix, 
is cleaved by matrix metalloproteinases (MMPs) generating the neo-epitope C1M. We investigated 
the association between serum-C1M and AMI and evaluated whether C1M is a prognostic marker for 
outcome following AMI. This study is based on The Prospective Epidemiological Risk Factor (PERF) 
Study including postmenopausal women. 316 out of 5,450 women developed AMI within the follow-up 
period (14 years, median). A multivariate Cox analysis assessed association between serum-C1M and 
AMI, and re-infaction or death subsequent to AMI. The risk of AMI increased by 18% (p = 0.03) when 
serum-C1M was doubled and women in the highest quartile had a 33% increased risk compared to 
those in the low quartiles (p = 0.025). Serum-C1M was, however not related to reinfarction or death 
subsequent to AMI. In this study C1M was be an independent risk factor for AMI. Measuring MMP 
degraded type I collagen could be useful for prediction of increased risk of AMI if replicated in other 
cohorts.
Coronary heart disease (CHD) affects mainly men but is also a leading cause of mortality in women1–3. The inci-
dence of AMI rises after menopause and the mean age of women with first-time AMI is higher than for men (72 
vs. 65 years)4. Mehta et al. reported in a Statement from American Heart Association that despite improvement 
in treatment modalities, women are more likely to die from acute myocardial infarction (AMI) than men1. For 
women AMI seems not to be studied adequately, misdiagnosed, and therefore left untreated. Additionally, evi-
dence for prognostic factors to predict adverse outcome after AMI in women is sparse5. There is a need for novel 
biomarkers that assess the risk and prognosis of AMI in women to improve survival5.
Atherosclerosis is an inflammatory process characterized by accumulation of plaques and plaque calcifica-
tion. Nodules erotion and rupture are complications leading to AMI and could be indicated by the epitope C1M. 
Plaque rupture is the most common cause of AMI by triggering the coagulation cascade whereby the risk of 
thrombosis is accelerated. A ruptured plaque has a necrotic core with an overlying thin fibrous cap infiltrated by 
inflammatory cells4,6 and expression of macrophage-released matrix metalloproteinases (MMPs) affects plaque 
stability7. MMP-induced proteolytic cleavage of collagen may weaken the fibrous cap and increase the risk of 
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plaque rupture, which will trigger the thrombotic cascade leading to AMI4,8–11 and detection of plaque instability 
is of interest.
Cavusoglu et al.4 report elevated MMP-3 levels in plasma to be associated with five-year-risk of AMI in men. 
In postmenopausal women, Dragsbaek et al.12 demonstrated the MMP-2, −9, and −13 generated type I collagen 
degradation fragment (C1M) to be associated with cardiovascular mortality. This study evaluated whether C1M 
is linked to AMI in postmenopausal women. C1M data presented by Dragsbaek et al.12 were further analysed to 
evaluate (i) association between serum-C1M and AMI in postmenopausal women and (ii) baseline serum-C1M 
as a biomarker for short-term prognosis following AMI.
Materials and Methods
Study population. This evaluation is based on the cohort “The Prospective Epidemiological Risk Factor 
(PERF) Study” which, in a prospective observational design includes Danish postmenopausal women to inves-
tigate age-related diseases. A detailed description of the cohort have previously been published13,14. The PERF 
study was conducted in accordance with Good Clinical Practice and approved by the Danish National Committee 
on Health Research Ethics (KA99070gm) with informed consent obtained from all subjects. Women who had 
participated in clinical randomized placebo-controlled studies or had been screened for the studies at the Centre 
for Clinical and Basic Research in Denmark were invited to participate in PERF. In 1999, 8,875 postmenopausal 
women were invited to attend a baseline examination. 5,855 women, aged 49–89 years consented to attend base-
line examination for the PERF study (between 1999–2001) with no other in- or exclusion criteria. For the present 
evaluation subjects without a record of AMI at baseline and with a complete dataset were selected for analysis. 
Thus, the study was conducted without a predefined sample size estimate.
Baseline. Fasting blood samples were collected and serum stored at −80 °C. Participants completed a phys-
ical examination by non-blinded staff including height and weight. Information in regard to physical activity, 
smoking, alcohol consumption, and diabetes was obtained through a structured interview questionnaire. Serum 
analysis, retrieval of information from The National Danish Patient Registry and The National Danish Causes of 
Death Registry were blinded.
Outcome Variables. In Denmark, all citizens are provided a unique personal identification number (CPR) 
that enables matching individuals to the Danish health registries. Data on AMI diagnosis, AMI date, cause and 
date of death were extracted from The National Danish Patient Registry and The National Danish Causes of Death 
Registry on 31/12/2014. Data from The National Danish Patient Registry and The National Danish Causes of 
Death Registry were matched with the PERF cohort. Diagnosis was classified in accordance with the International 
Classification of Diseases: Diagnosis code I21-I21.09 (AMI), tenth revision (ICD-10) or diagnosis code 410–410.9 
(AMI) for the eighth revision (ICD-8). Both AMI as diagnosis and cause of death during the follow-up were 
included until 31/12/2014. The secondary outcomes included subsequent AMI incidents. A secondary study out-
come (class A) was death (regardless of registered cause) or re-infarction within 28 days after an AMI according 
to the WHO definition15. Any outcome not involving death or re-infarction within 28 days was categorized as a 
class B outcome. For the purpose of defining classes A and B, the follow-up started on the day of the first AMI and 
ended at death within 28 days thereafter, re-infarction within 28 days from the AMI, or on 31/12/2014, whichever 
came first. Additional episodes of re-infarction or death related to a recurrent infarct were not included in the 
analysis.
Matrix Metalloproteinase Mediated Type I Collagen Degradation. A matrix metalloproteinase 
(MMP)-linked immunosorbent assay (ELISA), which detects serum fragments of type I collagen generated by 
MMP-2, −9, and −13 (termed C1M) was developed and validation with assay variability is published16. While 
other biomarkers of type I collagen fragments exist and used as measure of bone turnover17–19, the MMP gen-
erated fragment is destroyed by cathepsin-K indicating that this collagen fragment is not derived from bone 
turnover. The C1M fragment was analysed prior to previous studies and found to be stable after storage of serum 
at −80 °C for 12 years. In short, C1M stability was at the same time confirmed by seven consecutive freeze-thaw 
cycles with no significant variation in detected levels. Three-year stability studies were performed at the same 
time to validate C1M detection by measuring the same sample with a one-year interval12. The association between 
C1M levels and age at baseline was tested with a Pearson-correlation and found not to be significant (r = 0.01, 
p = 0.45). Finally, the C1M levels are comparable to those found in other cohorts. No blood samples and thus no 
measurements of C1M from the time of infarction were available.
Statistical Analysis. Data are presented as median with interquartile range (IQR) if not otherwise specified. 
Analyses were performed in MedCalc® (version 14.8.1) and RStudio® (version 3.3.1) and a p-value <0.05 was 
considered significant. The study population was stratified in two groups: A group included participants who 
were found to develop AMI and a group who did not develop AMI during the follow-up. Baseline characteris-
tics were compared using a Mann-Whitney test for numerical variables. Categorical variables were compared 
using a Chi-square test. The cohort was divided into quartiles based on serum-C1M levels: Q1: 21.2–31.1 ng/
mL (n = 1,406), Q2: 31.4–39.5 ng/mL (n = 1,392), Q3: 39.6–56.0 ng/mL (n = 1,384), and Q4: 56.1–2240 ng/mL 
(n = 1,389). A Kaplan-Meier Survival Curve was applied to demonstrate incident events of AMI over time in 
relation to the four quartiles of C1M-levels. Multivariate Cox proportional hazard analysis assessed association 
between C1M levels and incident AMI. Event-free mortality was included as a competing risk by censoring. The 
follow-up time since baseline was the time scale. All further analyses were conducted with C1M-quartiles, Q1–3 
vs. Q4, and log2-transformed serum-C1M levels. The Q1–3 vs. Q4 cut off was chosen based on results from the 
Kaplan-Meier Survival Curve. The analysis was adjusted for potential confounders including “Major Risk Factors 
and Coronary Heart Disease” (age, BMI, diabetes mellitus, hypertension, serum-cholesterol, tobacco smoking 
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and physical inactivity) according to American Heart Association20 and alcohol consumption ≥7 units/week cf. 
recommendation by the Danish Health Authority in regard to elderly21. Age, BMI, serum-cholesterol and -C1M 
were included in the analysis as numerical variables. The categorical variables were (i) diabetes divided into no, 
insulin-dependent or noninsulin-dependent, (ii) hypertension categorized as presence of hypertension or no 
hypertension, blood pressure systolic >139 mmHg or diastolic >89 mmHg22, (iii) smoking classified as never, 
previous or current, (iiii) level of physical activity grouped in relation to engagement in activities other than daily 
living, and (iiiii) use of alcohol defined as consumption of more or less than 7 units per week (15 mL or 12 g of 
pure alcohol). The multivariate Cox analysis was likewise used to evaluate serum-C1M as a prognostic marker 
for AMI outcome within 28 days after the event. The proportional-hazard assumption was checked by interacting 
covariates over time within the model adhering to STROBE guidelines.
Results
Study Population. 5,855 participants were screened, but 73 subjects had a record of AMI before baseline 
and serum-C1M was missing for 211 women. Thus, the study population included 5,571 (Fig. 1) of whom 316 
developed AMI during the follow-up. In 121 participants there were missing data (such as blood pressure, BMI, 
serum-cholesterol, diabetes) and the statistical analyses on a full data set involved 5,450 women with AMI occur-
ring in 309 (5.7%) participants. In comparison, 18 (5.4%) events of AMI occurred in women who were excluded 
(n = 332) with no statistical difference between the two groups (p = 0.85). The median (IQR) follow-up time was 
14.0 years (13.7–14.4) and time to AMI 6.5 years (2.9–10.5); for subjects in Q1 6.4 (3.2–10.9), Q2 7.3 (2.7–11.4), 
Q3 8.8 (3.6–10.8), and Q4 5.1 years (2.5–9.8).
Baseline Characteristics. Table 1 summarizes baseline characteristics for the included participants. Their 
age ranged from 51 to 86 years (70.9 (65.5–75.5), median with IQR) and women with AMI were older. The 
population had a BMI of 25.7 (23.2–28.7) kg/m2 of which the AMI group had the highest value. Additionally, 
serum-cholesterol was 6.3 (5.6–7.0) mmol/L with higher levels in the AMI group. Likewise, in women with AMI, 
7.1% presented with diabetes and 78.3% with hypertension compared to only 2.6% and 67%, respectively, in 
women without AMI. In addition, the prevalence of current smokers was higher in the AMI group whereas previ-
ous smokers dominated the non-AMI group. The proportion of participants with significant alcohol consumption 
was similar in the two groups, but the AMI group was less physically active.
C1M and AMI. Serum-C1M was 39.5 (31.3–56.0) ng/mL and highest in subjects with incident AMI during 
the study (43.7 (32.3–66.0) vs. 39.4 (31.2–50.7); p = 0.005). Hence, participants with AMI demonstrated an 11.5% 
higher serum-C1M when data were evaluated unfiltered by a potential influence of risk factors.
Figure 2 is the Kaplan-Meier Survival Curve, stratified in quartiles of C1M to illustrate the association between 
C1M and AMI. The plot shows a decrease in AMI-free survival rate for women with baseline serum-C1M levels 
in the upper quartile (Q4) compared to women with C1M levels in the lower quartiles (Q1–Q3) (p = 0.0055).
Based on the results from Fig. 2 and to adjust for possible confounders, a multivariate Cox proportional-hazard 
analysis was performed. C1M was analysed as a continuous variable (log2 transformed), divided into quartiles 
and using a binary outcome (Q4 vs. Q1–3) (Table 2). The independent contribution of high C1M levels to develop 
AMI with analysis adjusted for age, BMI, diabetes mellitus, hypertension, serum-cholesterol, tobacco smoking, 
physical inactivity, and alcohol consumption is evaluated. The log2-tranformed C1M analysis found that with a 
doubled given C1M-level, the hazard ratio for AMI increases by 18% (p = 0.03). For women with C1M-levels in 
the highest quartile the risk for AMI increased by 33% compared to C1M-levels in the quartile 1–3 (p = 0.025).
In Table 3, evaluation on class A vs. B outcomes in relation to C1M levels are presented with 117 (A) and 199 
(B) women classified. The class A outcomes included reinfarction n = 54, recurrent AMI as cause of death n = 55, 
and death within 28 days after recurrent AMI (registered cause other than AMI) n = 8. With analysis adjusted for 
Figure 1. Flow-chart, study population.
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Variable Total (n = 5,450) AMI (n = 309) No-AMI (n = 5,141) P-value AMI vs no-AMI
Age (years) 70.9 (65.5–75.5) 74 (69.1–78.2) 70.7 (65.3–75.3) <0.001
BMI (kg/m2) 25.7 (23.2–28.7) 26.7 (23.9–29.3) 25.7 (23.2–28.6) 0.005
Diabetes
    Insulin-dependent 121 (2.2%) 16 (5.2%) 105 (2.0%) <0.001
    Noninsulin-dependent 34 (0.6%) 6 (2.0%) 28 (0.5%) <0.001
Diastolic blood pressure 
(mmHg) 81 (74–90) 82 (75–91) 81 (74–90) 0.2823
Systolic blood pressure (mmHg) 148 (133–166) 155 (140–174) 148 (132–165) <0.0001
Hypertension 3686 (67.6%) 242 (78.3%) 3444 (67%) <0.001
Serum-cholesterol (mmol/L) 6.3 (5.6–7.0) 6.4 (5.8–7.1) 6.3 (5.6–7.0) 0.04
Smoking
    Previously 1660 (30.5%) 84 (27.2%) 1576 (30.7%) 0.009
    Current 1204 (22.1%) 91 (29.4%) 1113 (21.6%) 0.0016
Alcohol (≥7 units/week) 1789 (32.8%) 86 (27.8%) 1703 (33.1%) 0.063
Physical inactivity 1673 (30.7%) 118 (38.2%) 1555 (30.2%) 0.004
Serum-C1M (ng/mL) 39.5 (31.3–56.0) 43.7 (32.3–66.0) 39.4 (31.2–50.7) 0.005
Serum-C1M
    Q1 1374 (25.2%) 66 (21.4%) 1308 (25.4%)
0.0086
    Q2 1360 (25.0%) 71 (23.0%) 1289 (25.1%)
    Q3 1357 (24.9%) 70 (22.7%) 1287 (25.0%)
    Q4 1359 (24.9%) 102 (33.0%) 1257 (24.5%)
Table 1. PERF cohort baseline characteristics: Selected variables cf. American Heart Associations “Major Risk 
Factor and CHD”. The variables are given as percentage or median (IQR).
Figure 2. Kaplan-Meier Survival Curve of C1M quartiles. The lowest quartile, C1M-Q1, is illustrated in black, 
C1M-Q2 is illustrated in green, C1M-Q3 is illustrated in blue and the highest quartile of C1M-Q4 is illustrated 
in red. Cutoff C1M >56 ng/mL.
Variable Hazard ratio 95% confidence interval P-value
C1M-Q
Q1
Q2
Q3
Q4
C1M-cutoff
Ref.
1.06
1.0
1.35
1.33
[0.76; 1.48]
[0.71; 1.40]
[0.98; 1.87]
[1.04; 1.70]
0.75
0.98
0.068
0.025*
Log2-C1M 1.18 [1.02; 1.38] 0.03*
Table 2. Multivariate Cox proportional-hazard analysis for C1M-levels divided into quartiles associated with 
AMI. Corrected for age, body mass index, diabetes mellitus, hypertension, serum-cholesterol, tobacco smoking, 
physical inactivity, and alcohol consumption. *p < 0.05.
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age, data failed to reach statistical significance illustrating that C1M was not able to predict prognosis within 28 
days following an AMI.
Discussion
This study is based on data from the PERF study including Danish postmenopausal women and assessed whether 
serum-C1M is associated to risk of AMI. C1M was evaluated for its potential to reflect an unstable atherosclerotic 
plaque and consequently whether elevated C1M levels is associated with risk of plaque rupture and thrombosis. A 
second aim was to evaluate whether C1M correlates to outcome within a short period subsequent to AMI.
The study demonstrates that a high C1M (>56 ng/mL), as a surrogate for MMP mediated type I collagen 
tissue remodelling16, is associated with risk of AMI in postmenopausal women, independent of overweight, dia-
betes, hypertension, hyperlipidaemia, smoking, alcohol consumption, and inactivity. Within a 14-year follow-up 
period, postmenopausal women with high C1M levels (>56 ng/mL) demonstrated a 33% higher risk for AMI 
compared to women with C1M levels in the lower quartiles. Thus, the data suggest C1M as a biomarker for 
increased risk of AMI in postmenopausal women. This study did, however not demonstrate C1M as a prognostic 
marker for outcome following the first AMI, when C1M is measured prior to first AMI.
Due to an ageing population and improved therapeutic options for cardiac diseases the prevalence of cardi-
ovascular diseases is increasing and triggers morbidity, mortality, and increased health care costs. According to 
the WHO 2014 Global Status Report on non-communicable diseases, CVD is the leading cause of death. In 2012, 
approximately 17.5 million people died from CVD and of these 7.4 million (42.3%) died because of AMI. Thus, 
improved methods to assess the risk of AMI are warranted.
We measured MMP-degraded type I collagen because increased levels of C1M could reflect breakdown and 
destabilisation of the fibrous cap of an atherosclerotic plaque. Plaque instability and subsequent rupture lead-
ing to trombosis is thought to occur due to destruction of the fibrous cap, rich in type I collagen, mediated by 
macrophage-derived MMPs8,23–25. This study showed that C1M, reflecting MMP-mediated breakdown of collagen 
type I in the fibrous cap, is associated with AMI. This hypothesis is supported by Cavusoglu et al.4 in a study of 355 
male veterans referred to diagnostic coronary angiography. They found plasma MMP-3 (at a pre-specified cut-off 
of 20.56 ng/mL) associated to 5-year risk of AMI. The risk of plaque rupture is difficult to detect6 with plaque sta-
bility investigated by Near-Infrared Spectroscopy, laser based imaging, and Polarization-Sensitive Tomography, 
but success has been limited6,9,10,25.
High levels of C1M were associated with increased risk of AMI in postmenopausal women. To our knowledge 
we are the first to investigate MMP-degraded collagen in relation to risk of AMI. However, other extracellular 
matrix proteins have been investigated in relation to AMI and mortality. The endothelium is topped with glycoc-
alyx and syndecan-1 is a biomarker of glycocalyx degradation. Ostrowski et al.26 examined plasma syndecan-1 in 
571 patients with ST-myocardial infarction treated by percutaneous coronary intervention and a high syndecan-1 
level was independently correlated to 30-day cardiovascular- and all-cause mortality in two univariate analyses 
(p = 0.012 and p = 0.002). However, when adjusting for cardiovascular risk factors, the predictive value for mor-
tality within 30 days became insignificant and syndecan-1 did not associate to reinfarction within that time frame. 
The multivariate Cox analysis on the prognostic value of C1M for re-infarction or death after AMI was also not 
significant may be because the blood samples were collected up to 15 years prior to the AMI.
Plasma-MMP-3, syndecan-1, and here serum-C1M demonstrate potential new biomarkers for identification 
of subjects with elevated risk of AMI, but C1M was not a prognostic marker for risk of death or re-infarction 
subsequent to AMI. Yet, Dragsbaek et al.12 found C1M associated to mortality and the level of C1M at the time of 
AMI may be related to outcome, e.g. mortality and could be determined immediately after AMI.
The strength of this paper includes a large and homogenous population without inclusion- or exclusion cri-
teria and the participants are considered to be representative for Danish postmenopausal women. Additionally, 
the access to Danish patient registries is valuable; registry-linkage collected outcome information implies limited 
loss of data. Limitations are also identified. Autopsies are seldom performed when elderly Danes die even unex-
pectedly and some cases of AMI may not have been identified rendering a potential bias in the age composition of 
the population. Additionally, information about medication was not available and blood samples were collected 
up to 14.4 years prior to AMI. Thus, analysis of C1M association with short-term outcome following AMI would 
likely improve had C1M been obtained at that time. Thus, in this study C1M is a novel marker for long-term 
risk assessment. CRP measurements were unavailable for this cohort. Moreover, the potential link between 
cardiovascular- and connective tissue disease was not addressed and diagnostic criteria for AMI have changed 
during the follow-up27. Finally, Danish geography and organization of health care may not necessarily apply to 
Variable
Hazard 
ratio
95% confidence 
interval P-value
C1M-Q
Q2
Q3
Q4
C1M-cutoff
1.33
0.78
1.33
1.29
[0.77; 2.30]
[0.43; 1.43]
[0.79; 2.24]
[0.88; 1.89]
0.31
0.42
0.28
0.19
Log2-C1M 1.18 [0.79; 1.26] 0.97
Table 3. Multivariate Cox proportional-hazard analysis for baseline C1M as a prognostic marker for reinfarct 
or death within 28 days as a measure of short-term AMI outcome following the first AMI, regardless of when 
the first AMI occurred.
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other countries and as the data are restricted to postmenopausal Danish Caucasian women, the conclusions may 
not be generalized to the overall population.
In conclusion, in this study including postmenopausal women serum-C1M was associated to development 
of AMI and high levels seems to be an independent risk factor prior to AMI. External validation is warranted to 
confirm the results of this paper.
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